New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) in...

Full description

Saved in:
Bibliographic Details
Main Authors: Kazuhiko Uchiyama, Tomohisa Takagi, Yasunori Iwamoto, Norihiko Kondo, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiro Katada, Osamu Handa, Takeshi Ishikawa, Hiroaki Yasuda, Junichi Sakagami, Hideyuki Konishi, Nobuaki Yagi, Yuji Naito, Yoshito Itoh
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2014
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975

Similar Items